IP Library Patent Application 11982325
Patent Application
App. No. 11/982,325

Method and medicament for inhibiting the expression of a given gene

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/982,325
Abstract

The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA.

Claims (20)

1 .- 3 . (canceled)

4 . A method for stabilizing a double stranded RNA (dsRNA) consisting of two separate oligoribonucleotide strands for use in reducing expression of a target gene in a cell comprising:

a. providing a first oligoribonucleotide strand, wherein said first oligoribonucleotide strand is between 15-25 nucleotides in length and comprises a nucleic acid sequence fully complementary to a portion of an mRNA transcript of said target gene,

b. providing a second oligoribonucleotide strand which comprises a nucleic acid sequence complementary to said first strand,

c. hybridizing said first strand to said second strand under conditions that allow the formation of a dsRNA, and

d. linking said first and second strands to reduce dissociation compared to non-linked RNA strands, wherein said linking is in addition to the cohesion caused by the nucleotide pairs in the double stranded region.

5 . The method of claim 4 , wherein said chemical linkage is formed by a covalent bond or hydrogen bound.

6 . The method of claim 4 , wherein at least one of said oligoribonucleotide strands comprises at least one chemically modified nucleotide.

7 . The method of claim 5 , wherein at least one of said oligoribonucleotide strands comprises at least one chemically modified nucleotide.

8 . The method of claim 6 , wherein said chemically modified nucleotide is a 2′-modified nucleotide.

9 . The dsRNA of claim 8 , wherein said 2′-modified nucleotide is a 2′-methyl substituted nucleotide.

10 . The dsRNA of claim 8 , wherein said 2′-modified nucleotide is a 2′-amino substituted nucleotide.

11 . The dsRNA of claim 6 , wherein said chemically modified nucleotide is a blocked nucleotide.

12 . The method of claim 4 , wherein said first oligoribonucleotide strand is between 15-21 nucleotides in length.

13 . The method of claim 4 , wherein said first oligoribonucleotide strand is 21 nucleotides long.

14 . The method of claim 4 , wherein said chemical linkage is formed by a linkage selected from the group consisting of poly(oxyphosphinicooxy-1,3-propandiol), polyethylene glycol, methylene blue, bis(2-chloroethyl)amine, and N-acetyl-N′-(p-glyoxyl-benzoyl)cystamine.

15 . The method of claim 4 , wherein said chemical linkage is a C18 linker.

16 . The method of claim 4 , wherein the target gene is a mammalian gene or a viral gene.

17 . The method of claim 4 , wherein the target gene is selected from the group consisting of an oncogene, a cytokine gene, an Id protein gene, a developmental gene, a PKR gene and a prion gene.

18 . The method of claim 4 , wherein said cell is a mammalian cell.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2009
From: ALNYLAM EUROPE AG
To: ALNYLAM PHARMACEUTICALS, INC.
Reel/Frame 023070/0300 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2008
From: LIMMER, STEFAN; KREUTZER, ROLAND
To: RIBOPHARMA AG
Reel/Frame 020473/0410 →
CHANGE OF NAME Recorded Feb 6, 2008
From: RIBOPHARMA AG
To: ALNYLAM EUROPE AG
Reel/Frame 020476/0003 →